(IGXT)Mcap 23 M/ 2xNDA filing & Profitable THIS YEAR
BIG PARTNERSHIPS NEWS THIS Q + PROFITABILITY IN THIS YEAR = A LIFETIME OPPORTUNITY HERE .THE MOST INVESTORS STILL NOT REALIZE THE POTENTIAL IN THIS LOW FLOAT MONSTER .GLTA
Partnership news THIS Q and 2 new NDA filings later this year !!! 9 drugs in Pipeline including a Blockbuster all these drugs will be on the Market within 2-3 years !
Burn rate is only 1.2 M a year = cash untill late 2014 EXCLUDING upfront payments from upcoming Partnerships and EXCLUDING cpi-300 revenue.
Price Target : $3-5 within 12-18 Months ! Please do your own DD and realize the MONSTER POTENTIAL in this Goldmine !
Market Cap : $ 23.5 M Cash: $ 4.3 M Price : 0.50 $ NO DEBT
Shares Out : 46 M ( 29 M shares are held by Insiders + Institutions)
On 11/10/10 IntelGenx (TSX-V: IGX, US: IGXT) announced that FDA has approved CPI-300, their high dose version of Biovail's (now Valeant's) top-selling drug Wellbutrin XL (Bupropion HCl). This will make CPI-300 the ONLY FDA approved high-dose bupropion HCl on the U.S. market.
This approval is a significant symbolic win for the company. IntelGenx developed CPI-300 completely on their own and along the way prevailed against Biovail in a year-long patent infringement lawsuit. So the company has demonstrated the capability and tenacity to see a product through development to approval which should translate into higher value being placed on their pipeline.
This approval will also be a significant financial win for the company. IntelGenx owns the entire rights to CPI-300 and now will look to close a commercial partnership in short order. Who the partner will be and how the economics (i.e. upfront & royalty) will look is too tough to predict, but once the product is launched in 2012 the company should become cash flow positive almost instantly.
The company's pipeline is also full of thin film products, so there should be steady news flow on human studies, partnerships and new product developments. Intelgenx is only one of a handful of companies with technology in this area.